Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 5/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.44 |
| ▸ | ATR | Q13535 | 12/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15465690 | 1.00 | CYP4F2 (0.44) | CYP4F2CYP4A11ATRRXRARXRB | |
| SCHEMBL15465183 | 0.99 | CYP4F2 (0.44) | CYP4F2CYP4A11ATRRXRARXRB | |
| SCHEMBL18192102 | 0.99 | CYP4F2 (0.44) | CYP4F2CYP4A11ATRRXRARXRB | |
| SCHEMBL15465184 | 0.99 | CYP4F2 (0.44) | CYP4F2CYP4A11ATRRXRARXRB | |
| SCHEMBL20958953 | 0.82 | CYP4F2 (0.42) | CYP4F2CYP4A11ATRRXRARXRB | |
| SCHEMBL24947689 | 0.79 | CYP4F2 (0.46) | CYP4F2CYP4A11ATRRXRARXRB | |
| SCHEMBL20516645 | 0.78 | CYP4F2 (0.42) | CYP4F2CYP4A11ATRRXRARXRB | |
| SCHEMBL20516647 | 0.78 | CYP4F2 (0.42) | CYP4F2CYP4A11ATRRXRARXRB | |
| SCHEMBL23429555 | 0.78 | CYP4F2 (0.42) | CYP4F2CYP4A11ATRRXRARXRB | |
| SCHEMBL15465136 | 0.74 | ATR (0.42) | CYP4F2CYP4A11ATRRXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2974730-B1 | DRUG FOR RESPIRATORY DISEASES | DAIICHI SANKYO CO LTD (JP) | 2018-01-31 | — | — | EP | disclosed |
| EP-3144300-B1 | METHODS OF PRODUCING 4-CYCLOALKYLOXYBENZENESULFONAMIDES | DAIICHI SANKYO CO LTD (JP) | 2017-12-20 | — | — | EP | disclosed |
| US-9845313-B2 | Cycloalkane derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-12-19 | — | — | US | disclosed |
| EP-3144300-A1 | METHODS OF PRODUCING 4-CYCLOALKYLOXYBENZENESULFONAMIDES | Daiichi Sankyo Company, Limited (JP) | 2017-03-22 | — | — | EP | disclosed |
| US-9597330-B2 | Drugs for treating respiratory diseases | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-03-21 | — | — | US | disclosed |
| US-20170001984-A1 | CYCLOALKANE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-01-05 | — | — | US | disclosed |
| US-9493448-B2 | Cycloalkane derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-11-15 | — | — | US | disclosed |
| EP-2813491-B1 | CYCLOALKANE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-11-02 | — | — | EP | disclosed |
| US-20160038486-A1 | DRUG FOR RESPIRATORY DISEASES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-02-11 | — | — | US | disclosed |
| EP-2974730-A1 | DRUG FOR RESPIRATORY DISEASES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-20 | — | — | EP | disclosed |
| EP-2813491-A1 | CYCLOALKANE DERIVATIVE | Daiichi Sankyo Co., Ltd. (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-8889741-B2 | Cycloalkane derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-11-18 | — | — | US | disclosed |
| US-20140045862-A1 | Cycloalkane Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160038486-A1 | DRUG FOR RESPIRATORY DISEASES | SCN1B, NHERF1, SCNN1A | CYP4F2 1449/4885CYP4A11 764/4885ATR 4280/4885 |
| US-20170001984-A1 | CYCLOALKANE DERIVATIVES | TRPV1, TRPA1, SCNN1A | CYP4F2 2573/4885CYP4A11 2205/4885ATR 4771/4885 |
| US-20140045862-A1 | Cycloalkane Derivatives | TRPV1, TRPA1, SCNN1A | CYP4F2 2573/4885CYP4A11 2205/4885ATR 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.